Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 291

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 291
---
     
    Consent of PricewaterhouseCoopers LLP, independent registered accounting firm

    X

    31.1
     
    Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002

    X

    31.2
     
    Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002

    X

    32.1
     
    Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350

    X

    97.1
     
    Compensation Clawback Policy
     
    10-K
     
    97.1
     
    2/27/24

    101
     
    The following materials from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language): (i)   Consolidated Balance Sheets(ii)  Consolidated Statements of Operations and Comprehensive Loss(iii) Consolidated Statements of Stockholders’ Equity(iv) Consolidated Statements of Cash Flows(v)  Notes to Consolidated Financial Statements

    X

    104
     
    The cover page from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 formatted in Inline XBRL (included in Exhibit 101)

* Management contract or compensatory plan or arrangement.

† Portions of this exhibit have been omitted.

The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are not deemed filed with the SEC and are not to be incorporated by reference into any filing of REGENXBIO Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.

130

SIGNATURES

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 13, 2025.

    REGENXBIO INC.

    By:
     
    /s/ Curran Simpson

    Curran SimpsonPresident and Chief Executive Officer